LYKA LABS LTD.

Lyka Labs Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, until 48 hours after the announcement of the company's unaudited financial results for the second quarter ending September 30, 2026. This measure is intended to prevent potential insider trading during the sensitive period leading up to the financial results disclosure.

Lyka Labs Ltd has submitted a revised press release for its unaudited financial results for the quarter ended June 30, 2026. The revision corrects typographical errors in specific financial figures from the original filing on August 10, 2026. Key unaudited figures for Q1 FY27 include a standalone net total income increase of 42.67% to ₹4272.79 Lacs and a consolidated net total income increase of 26.95% to ₹4272.79 Lacs. Standalone net profit surged by 159.06% to ₹210.03 Lacs, while consolidated net profit rose by 105.44% to ₹204.66 Lacs. The company attributes revenue growth to strong performance in domestic and export markets, particularly in branded formulations and veterinary products. Standalone EBITDA margin decreased slightly to 11.84% from 14.16% year-on-year, and consolidated EBITDA margin fell to 11.74% from 13.07%. The company has requested the revised press release be taken on record and updated on its website.

Lyka Labs Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a significant surge in net profit, with standalone net profit increasing by 159.04% to ₹210.01 Lacs and consolidated net profit rising by 105.44% to ₹204.66 Lacs. Standalone Net Total Income grew by 42.67% to ₹4272.79 Lacs, while consolidated Net Total Income increased by 26.95% to ₹4272.79 Lacs. Domestic revenue saw a 15.91% rise, and export revenue jumped by 68.03%. However, EBITDA margins declined both on standalone and consolidated bases compared to the previous year's quarter. The Board of Directors approved these financial results in a meeting held on August 10, 2026.

Lyka Labs Ltd announced that its Board of Directors, in a meeting held on August 10, 2026, approved the unaudited financial results for the first quarter ended June 30, 2026. The company also approved the divestment of its entire 100% equity stake in its subsidiary, Lyka BDR International Limited. Lyka BDR International Limited is confirmed not to be a material subsidiary. The limited review report on the financial results and further disclosures regarding the divestment are attached. The board meeting commenced at 11:00 AM and concluded at 12:20 PM.

Lyka Labs' consolidated revenue for the quarter ended 30 June 2026 rose 28.1% YoY to ₹42.31 Cr from ₹33.03 Cr, while consolidated PAT more than doubled YoY to ₹2.05 Cr from ₹1.00 Cr — a print that also reverses the ₹8.07 Cr consolidated loss booked in the March-2026 quarter. PBT grew a more modest 44% YoY to ₹1.95 Cr; the extra lift to PAT came from a ₹0.10 Cr deferred-tax credit versus a ₹0.05 Cr tax charge a year ago, so the bottom-line gain overstates the operating improvement. NPM (PAT/total income) rose to 4.79% from 2.96% YoY, but OPM was essentially flat at 10.75% against 11.16% a year ago — cost ratios for materials, employee expense and other overheads moved only marginally — making this more a tax-and-base-effect story than a margin-expansion one. Standalone tracks closely (revenue ₹42.31 Cr, PAT ₹2.10 Cr, EPS ₹0.58 vs ₹0.22 YoY); the ₹0.05 Cr gap to consolidated PAT is the subsidiary Lyka BDR International's own quarterly loss. On the same day, the board also approved 100% divestment of Lyka BDR International — a subsidiary that contributed 8% of FY26 consolidated income (₹10.55 Cr) and carries a negative net worth of ₹4.49 Cr — with sale terms, buyer and consideration still to be finalised and delegated to the Audit Committee. Separately, the NCLT-sanctioned merger of Lyka Export Limited into Lyka Labs (order dated 16 March 2026) is now reflected in restated prior-period figures under Ind AS 103. There is no formal management guidance on record for this company, and a web search for Q1 FY27 previews/estimates turned up no analyst or brokerage coverage for this micro-cap, so both vs-guidance and vs-street are unknown; the filing itself carries no separate management commentary beyond the standard board-outcome letter. The subsidiary sale terms and whether the deferred-tax credit that flattered this quarter's PAT persists are the two items likely to matter more to the trend than this quarter's headline number.

Lyka Labs Ltd has announced that its Board of Directors will convene on August 10, 2026. The primary agenda item for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company will also review the Limited Review Report from its statutory auditor. The financial results and related documents will be made available on the company's website, www.lykalabs.com.

Lyka Labs Ltd has announced its 47th Annual General Meeting (AGM) will be held on August 10, 2026, at 12:30 p.m. via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting will transact business as outlined in the notice, which, along with the Annual Report for FY 2025-26, has been emailed to shareholders. Physical copies have been dispensed with as per MCA and SEBI circulars. The Annual Report is also available on the company's website. The company is providing e-voting facilities through NSDL, with remote e-voting commencing on August 6, 2026, and concluding on August 9, 2026. A cut-off date of August 3, 2026, has been set for determining voting eligibility.

Lyka Labs Ltd has announced its 47th Annual General Meeting (AGM) scheduled for August 10, 2026, at 12:30 PM IST, to be conducted via Video Conferencing/Other Audio Visual Means. In compliance with SEBI Listing Regulations, the company has dispatched letters to shareholders without registered email addresses, providing a weblink to access the Annual Report for FY 2025-26 on their website (www.lykalabs.com/annual_reports.html). The company also reminded shareholders to update KYC details and dematerialize physical securities as per SEBI's master circular, emphasizing electronic mode for payments for those with incomplete KYC. Investor queries can be directed to investor.helpdesk@in.mpms.mufg.com or through their website's helpdesk.

Lyka Labs Ltd has filed its Annual Report for the Financial Year 2025-26, along with the Notice of the AGM and other Statutory Reports. The report is being sent electronically to members with registered email addresses. Shareholders whose emails are not registered will receive a letter with a web-link to access the report. The 47th Annual General Meeting is scheduled for August 10, 2026, to be held via Video Conferencing. Key agenda items include adoption of financial statements, appointment of a director, and ratification of cost auditor remuneration.

Lyka Labs Ltd has announced its 47th Annual General Meeting (AGM) to be held on August 10, 2026, at 12:30 PM IST via Video Conferencing. The agenda includes the adoption of audited financial statements for FY 2025-26, appointment of a director, and ratification of remuneration for cost auditors for FY 2025-26 and FY 2026-27. Additionally, the company will consider approval of material related party transactions with IPCA Laboratories Limited for FY 2026-27. The notice of the AGM is part of the Annual Report 2025-26, available on the company's website.